Results 21 to 30 of about 1,611 (152)
Frontiers in Neuroanatomy, 2022 Pituitary adenylate cyclase-activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) are structurally related neuropeptides that are widely expressed in vertebrate tissues. The two neuropeptides are pleiotropic and have been associated with
Anne Marie Lund +3 more
doaj +1 more source
Effects of VPAC1 activation in nucleus ambiguus neurons [PDF]
Brain Research, 2017 The pituitary adenylyl cyclase-activating polypeptide (PACAP) and its G protein-coupled receptors, PAC1, VPAC1 and VPAC2 form a system involved in a variety of biological processes. Although some sympathetic stimulatory effects of this system have been reported, its central cardiovascular regulatory properties are poorly characterized.
Florin Liviu, Gherghina +5 more
openaire +2 more sources
Clinical Relevance of VPAC1 Receptor Expression in Early Arthritis: Association with IL-6 and Disease Activity. [PDF]
PLoS ONE, 2016 The vasoactive intestinal peptide (VIP) receptors VPAC1 and VPAC2 mediate anti-inflammatory and immunoregulatory responses in rheumatoid arthritis (RA).
Iria V Seoane +8 more
doaj +1 more source
European Journal of Histochemistry, 2022 Pituitary adenylate cyclase-activating polypeptide (PACAP) plays an important role in the steroidogenesis and spermatogenesis in the testis through its receptors PAC1, VPAC1, and VPAC2.
Zeqi Tang +7 more
doaj +1 more source
Urinary VPAC1: A potential biomarker in prostate cancer
AIMS Allergy and Immunology, 2022 <abstract> <p>Prostate cancer is ranked as the fourth most prevalent cancer commonly diagnosed among males over 40 years of age, according to the WHO Cancer Fact Sheet 2020, and it is additionally a leading cause of cancer mortality among males. The incidence of prostate cancer and mortality varied significantly across the globe.
Mansur Aliyu +3 more
openaire +1 more source
VPAC1 Receptors for Imaging Breast Cancer: A Feasibility Study [PDF]
Journal of Nuclear Medicine, 2013 VPAC1 encodes G-protein-coupled receptors expressed on all breast cancer (BC) cells at the onset of the disease, but not on benign lesions. Our extensive preclinical studies have shown that (64)Cu-TP3805 has a high affinity for VPAC1, is stable in vivo, and has the ability to distinguish spontaneously grown malignant BC masses from benign lesions.
Mathew L, Thakur +8 more
openaire +2 more sources
VPAC1 Targeted 64 Cu-TP3805 kit preparation and its evaluation [PDF]
Nuclear Medicine and Biology, 2017 Previously, our laboratory has shown that 64Cu-TP3805 can specifically target VPAC1 receptors and be used for positron emission tomography (PET) imaging of breast (BC) and prostate cancer (PC) in humans. Present work is aimed at the formulation of a freeze-dried diaminedithiol-peptide (N2S2-TP3805) kit and it's evaluation for the preparation of 64Cu ...
Sushil K, Tripathi +8 more
openaire +2 more sources
Macrophage Resistance to HIV-1 Infection Is Enhanced by the Neuropeptides VIP and PACAP. [PDF]
PLoS ONE, 2013 It is well established that host factors can modulate HIV-1 replication in macrophages, critical cells in the pathogenesis of HIV-1 infection due to their ability to continuously produce virus.
Jairo R Temerozo +4 more
doaj +1 more source
Biology, 2022 Vasoactive Intestinal Peptide binds with high affinity to VPAC1R and VPAC2R, thus regulating key physiologic functions. Previously, we documented in VIP−/− mice a leaner body phenotype and altered metabolic hormones.
Daniel Sanford +7 more
doaj +1 more source
Molecular Basis of Class B GPCR Selectivity for the Neuropeptides PACAP and VIP
Frontiers in Molecular Biosciences, 2021 The related neuropeptides PACAP and VIP, and their shared PAC1, VPAC1 and VPAC2 receptors, regulate a large array of physiological activities in the central and peripheral nervous systems.
Chenyi Liao +4 more
doaj +1 more source